Breaking News
Close
0

DarioHealth Reports Q1 Revenue of $8.06M, Net Loss of $9.9M

May 12, 2022 07:08
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

DarioHealth Corp. (Nasdaq: NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the first quarter 2022 and provided a corporate and commercial update.

"Our first quarter results reflect our increasingly successful transition to a B2B model with growing revenue and gross margins," stated Erez Raphael, Chief Executive Officer of Dario. "We increased revenue nearly 124% over the first quarter of last year and nearly 34% sequentially, and we expanded our gross margin on a GAAP basis to 49.4% and on a non-GAAP basis to 61%. Additionally, in light of the demonstrable traction and increasing revenue in the B2B (commercial) market segment, we continued to rationalize marketing spend in the direct-to-consumer segment resulting in improved margins which drove a significantly narrower net loss and cash burn rate as compared to the fourth quarter of 2021.With the strategic agreement executed with Sanofi (EPA:SASY) (NASDAQ:SNY) U.S. (Sanofi) and the $40 million financing that we closed in the quarter, we believe that we are in an excellent position to achieve our financial and operational goals for the foreseeable future," Mr. Raphael concluded.

"In addition to the innovative, multi-year collaboration that we announced with Sanofi, we had a very productive quarter, adding 14 new B2B contracts, including two additional health plans, which we expect will contribute revenues in the back half of this year," stated Rick Anderson, President and General Manager of North America. "We continue to see increasing interest and demand for our integrated, multi-chronic condition platform, which continues to grow, and we anticipate announcing many more customer conversions from our growing pipeline over the remainder of the year."

Q1 2022 and Recent Highlights

  • Generated total revenue of $8.06 million, representing an increase of 124% from the first quarter of 2021, and 34% from the fourth quarter of 2021.
  • Added 14 new accounts across the employer, health plan and provider channels during Q1, reflecting continued momentum of B2B segment.
  • Signed a multi-year, multi-faceted $30 million agreement with Sanofi to accelerate adoption of Dario's solution within the payer channel through joint sales efforts and drive innovation through shared research initiatives and development of new products for use on Dario's platform.
  • Expanded GAAP gross margins to 49.4% and non-GAAP gross margins to 61%.
  • Raised $40 million through a registered direct offering priced at the market.
  • Announced acquisition of Physimax, a leading provider of validated computer vision for musculoskeletal health.
  • Presented new clinical research demonstrating improved outcomes for participants using a single integrated digital solution to manage multiple chronic conditions at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference, held April 27th – 30th.

First Quarter 2022 Results Summary

Revenues for the first quarter ended March 31, 2022, were $8.06 million, a 34% sequential increase from fourth quarter ended December 31, 2021, and a 124% increase from the $3.6 million in the first quarter ended March 31, 2021. The increase in revenues resulted from increased revenues in our B2B commercial market segment.

Gross profit in the first quarter of 2022 was $4.0 million, an increase of $2.9 million, compared to gross profit of $1.1 million in the first quarter of 2021. Gross profit as a percentage of revenues increased from 30.1% in the first quarter of 2021 to 49.4% in the first quarter of 2022.

Pro-forma gross profit, excluding $932,000 of non-cash amortization of expenses related to the acquisition of technology, was $4.9 million, or 61% of revenues, for the three months ended March 31, 2022.

Total operating expenses for the first quarter of 2022 were $19.9 million compared with $15.4 million for the first quarter of 2021 and $22.2 million in the fourth quarter of 2021, an increase of $4.5 million, or 28.9%, compared to the first quarter of 2021, and a decrease of $2.3 million, or 10.6%, compared to the fourth quarter of 2021. The increase compared to the first quarter of 2021 resulted from an increase in our operating expenses. The decrease compared to the fourth quarter of 2021 resulted from a decrease in our direct to consumer marketing expenses. Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2022 were $14.8 million compared to $10.6 million for the first quarter of 2021, and $16.4 million in the fourth quarter of 2021.

Operating loss for the first quarter of 2022 was $15.9 million, an increase of $1.55 million, or 10.8%, compared to the $14.3 million operating loss in the first quarter of 2021, and a decrease of $5.8 million or 26.7% compared to the $21.7 million operating loss in the fourth quarter of 2021. The increase compared to the first quarter of 2021 was mainly due to the increase in our operating expenses, and the decrease compared to the fourth quarter of 2021 was mainly due to the increase in the gross profit and the decrease in operating expenses.

Net loss was $15.9 million in the first quarter of 2022, an increase of $0.9 million, or 6.3%, compared to the $15 million net loss in the first quarter of 2021, and a decrease of $5.7 million, or 26.3% compared to the fourth quarter of 2021. Net loss excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2022 was $9.9 million compared to $9.6 million for the first quarter of 2021 and $14.9 million in the fourth quarter of 2021.

Non-GAAP billings for the three months ended March 31, 2022, were $7.96 million, a 116% increase from $3.69 million reported for the three months ended March 31, 2021. The increase is a result of higher sales generated in the three months ended March 31, 2022, compared to the three months ended March 31, 2021. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

Conference Call Details: Thursday, May 12, 8:30am ET

Dial-in Number: 844-826-3035

International Dial-in: 412-317-5195

Conference ID: DarioHealth First Quarter 2022 Results Call

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1547229&tp_key=ae83ab1839

Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through June 12, 2022. To listen to the replay, dial 844-512-2921 (domestic) or 412-317-6671 (international) and use replay passcode 10166824.

DarioHealth Reports Q1 Revenue of $8.06M, Net Loss of $9.9M
 

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalised Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email